Biotech Values

[DewDiligence]

IDIX Insider Shareholdings

[Updated for departure of general counsel, John Weidenbruch
(#msg-53319051); although Weidenbruch stays until 8/31/10,
I’m taking the liberty of removing him from the table now.
Options listed below include vested and non-vested holdings.]

 
                             Shares     Options 

Officers
JP Sommadossi (CEO)‡ 2,219,754 1,806,250
Ron Renaud (CFO) 15,000 555,000
Doug Mayers (CMO) 30,000 300,000
David Standring (EVP/Bio) 67,575 150,000
Paul Fanning (SVP/HR) 1,333 235,000

Directors‡
Charles Cramb 7,200 160,000
Wayne Hockmeyer 41,708 120,000
Thomas Hodgson 92,324 120,000
Tamar Howson† 0 38,333
Denise Pollard-Knight 0 100,000
Robert Pelzer* 0 0
Anthony Rosenberg* 0 0
======================== ========= =========
All 12 insiders 2,474,894 3,884,583*Directors appointed by NVS do not directly own IDIX
shares or options, but NVS itself is a major shareholder.

‡Sommadossi is Chairman of the BoD.

†Joined BoD 3/30/10.